Role of vitamin D in targeting cancer and cancer stem cell populations and its therapeutic implications

Marigoudar, Jyoti Bharamgoud; Sarkar, Diptendu; Yuguda, Yakubu Magaji; Abutayeh, Reem Fawaz; Kaur, Avneet; Pati, Ankita; Mitra, Disha; Ghosh, Animikha; Banerjee, Debashis; Borah, Sudarshana; Barman, Kamallochan; Das, Bhanita; Khairnar, Shubham Jagdish; Šeherčehajić, Emir; Kumar, Shivam

doi:10.1007/s12032-022-01855-0

Cited by 7 publications

(5 citation statements)

References 83 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…VDR activation regulates calcium and phosphate metabolism, which are vital for maintaining skeletal health. Additionally, VDR activation influences cell differentiation and proliferation, and exhibits anti-inflammatory and anti-carcinogenic properties [ 35 ]. Recent research has suggested that VD exerts a protective effect against various cancer types.…”

Section: Discussionmentioning

confidence: 99%

Circulating vitamin D level before initiating chemotherapy impacts on the time-to-outcome in metastatic colorectal cancer patients: systematic review and meta-analysis

Ottaiano,

Iacovino,

Santorsola

et al. 2024

J Transl Med

View full text Add to dashboard Cite

Background Vitamin D (VD) is implicated in various health conditions, including colorectal cancer (CRC). To investigate potential relationships between pre-chemotherapy VD levels and the time-to-outcome in metastatic CRC patients, we conducted a systematic review and meta-analysis. Methods Following the PRISMA 2020 guidelines, we performed thorough searches in PubMed/MEDLINE and Scopus/ELSEVIER databases (covering the years 2002 to 2022). Inclusion criteria mandated studies to report on individuals aged 18 years and above with histologically confirmed stage IV CRC. Additionally, studies needed to provide data on VD levels before chemotherapy, along with hazard ratios (HR) and 95% confidence intervals (CIs) for overall survival (OS) and/or progression-free survival (PFS). Five articles were identified with the aim of establishing a combined risk estimate for death and progression based on pre-chemotherapy VD levels. Heterogeneity among studies and publication bias were evaluated using Tau2, I2 statistics, and a Funnel plot. Results Although no significant heterogeneity was observed in time-to-outcome among the selected studies, variations in technical assessments and serum VD concentration measurements were noted. The pooled analysis, involving 1712 patients for OS and 1264 patients for PFS, revealed a 47% increased risk of death (HR: 1.47, 95% CI: 1.21–1.79) and a 38% increased risk of progression (HR: 1.38, 95% CI: 1.13–1.70) for patients with lower VD levels, as indicated by fixed-effects models. Conclusions Our results emphasize the adverse effects of low VD concentration on the time-to-outcome in metastatic CRC patients. This underscores the importance of investigating VD supplementation as an innovative approach in this clinical setting to enhance patient outcomes.

show abstract

Section: Discussionmentioning

confidence: 99%

Circulating vitamin D level before initiating chemotherapy impacts on the time-to-outcome in metastatic colorectal cancer patients: systematic review and meta-analysis

Ottaiano,

Iacovino,

Santorsola

et al. 2024

J Transl Med

View full text Add to dashboard Cite

show abstract

“…Recently, a growing body of literature has focused on the association between VD and cancer [37]. Its active form, 1,25-dihydroxyvitamin D, binds to the VD receptor (VDR) in various tissues, including the bone, intestine, and immune cells.…”

Section: Discussionmentioning

confidence: 99%

Circulating Vitamin D Level and Its Impact on Mortality and Recurrence in Stage III Colorectal Cancer Patients: A Systematic Review and Meta-Analysis

Ottaiano

Facchini

Santorsola

et al. 2023

Cancers

View full text Add to dashboard Cite

Background: Vitamin D (VD) has been implicated in several diseases, including colorectal cancer (CRC). This study aimed to determine whether there is an association between VD levels and time-to-outcome in stage III CRC patients through a systematic review and meta-analysis. Methods: The study adhered to the PRISMA 2020 statement. Articles were searched in PubMed/MEDLINE and Scopus/ELSEVIER. Four articles were selected, with the primary objective of providing a pooled estimate of the risk of death specifically in stage III CRC patients based on pre-operative VD levels. Study heterogeneity and publication bias were analyzed using Tau2 statistics and funnel plots. Results: The selected studies showed significant heterogeneity regarding time-to-outcome, technical assessments, and serum VD concentration measures. The pooled analysis of 2628 and 2024 patients revealed a 38% and 13% increase in the risk of death (HR: 1.38, 95% CI: 0.71–2.71) and recurrence (HR: 1.13; 95% CI: 0.84–1.53), respectively, for random-effects models among patients with lower levels of VD. Conclusions: Our findings suggest that a low concentration of VD has a significant negative impact on time-to-outcome in stage III CRC.

show abstract

“…Its various actions, such as DNA damage repair and protecting against oxidative stress, can contribute to preservation of somatic stem cells. Additionally, calcitriol may inhibit the growth of cancer stem cells by inducing cell cycle arrest and promoting apoptosis ( 68 ). In summary, these vitamins collectively contribute to cancer defense and hold promise for improving cancer-related outcomes.…”

Section: Biological Activities Of Vitamins a C D E And Their Impact O...mentioning

confidence: 99%

Role of vitamins A, C, D, E in cancer prevention and therapy: therapeutic potentials and mechanisms of action

Talib,

Ahmed Jum’AH,

Attallah

et al. 2024

Front. Nutr.

View full text Add to dashboard Cite

Cancer, a leading global cause of mortality, arises from intricate interactions between genetic and environmental factors, fueling uncontrolled cell growth. Amidst existing treatment limitations, vitamins have emerged as promising candidates for cancer prevention and treatment. This review focuses on Vitamins A, C, E, and D because of their protective activity against various types of cancer. They are essential as human metabolic coenzymes. Through a critical exploration of preclinical and clinical studies via PubMed and Google Scholar, the impact of these vitamins on cancer therapy was analyzed, unraveling their complicated mechanisms of action. Interestingly, vitamins impact immune function, antioxidant defense, inflammation, and epigenetic regulation, potentially enhancing outcomes by influencing cell behavior and countering stress and DNA damage. Encouraging clinical trial results have been observed; however, further well-controlled studies are imperative to validate their effectiveness, determine optimal dosages, and formulate comprehensive cancer prevention and treatment strategies. Personalized supplementation strategies, informed by medical expertise, are pivotal for optimal outcomes in both clinical and preclinical contexts. Nevertheless, conclusive evidence regarding the efficacy of vitamins in cancer prevention and treatment is still pending, urging further research and exploration in this compelling area of study.

show abstract

Role of vitamin D in targeting cancer and cancer stem cell populations and its therapeutic implications

Cited by 7 publications

References 83 publications

Circulating vitamin D level before initiating chemotherapy impacts on the time-to-outcome in metastatic colorectal cancer patients: systematic review and meta-analysis

Circulating vitamin D level before initiating chemotherapy impacts on the time-to-outcome in metastatic colorectal cancer patients: systematic review and meta-analysis

Circulating Vitamin D Level and Its Impact on Mortality and Recurrence in Stage III Colorectal Cancer Patients: A Systematic Review and Meta-Analysis

Role of vitamins A, C, D, E in cancer prevention and therapy: therapeutic potentials and mechanisms of action

Contact Info

Product

Resources

About